浙江海正药业股份有限公司 关于第四次以集中竞价交易方式回购公司股份的进展公告

Group 1 - The company has approved a share repurchase plan with a total fund amount between RMB 50 million and RMB 100 million, with a maximum repurchase price of RMB 13 per share, and the repurchase period is within 12 months from the board's approval date [1] - As of the end of July 2025, the company has repurchased a total of 5,535,000 shares, accounting for 0.46% of the total share capital, with the highest purchase price at RMB 9.40 per share and the lowest at RMB 8.92 per share, totaling RMB 50,891,385.00 paid (excluding transaction fees) [1][2] - The company will continue to make repurchase decisions based on market conditions and will fulfill information disclosure obligations in a timely manner [3]